Trastuzumab: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner, Joel L. Sussman, Alexander Berchansky

@@ Line 7: / Line 7: @@
 * 2008 Sales: $4.75 Billion
 * Importance: It is a very effective treatment against HER2-positive metastatic breast [[cancer]] compared to other cancer therapies. Controversial due to its cost of nearly $100,000 per year. Is often pointed to as an example of the benefits of personalized medicine in which a patent's genetic profile is used to optimize their medication regimen.
-* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
+* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders
 ===Mechanism of Action===
@@ Line 15: / Line 15: @@
 {| class="wikitable" border="1" width="40%" style="text-align:center"
 |-
-!  colspan="12" align="center"| EGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>DOI: 10.1200/JCO.2003.12.109</ref><ref> B. Leyland-Jones, et al. Pharmacologic insights into the future of trastuzumab. Annals of Oncology 12 (Suppl. I): S43-S47, 2001.</ref>
+!  colspan="12" align="center"| EGFR Inhibitor [[Pharmacokinetics]]<ref>DOI: 10.1200/JCO.2003.12.109</ref><ref> B. Leyland-Jones, et al. Pharmacologic insights into the future of trastuzumab. Annals of Oncology 12 (Suppl. I): S43-S47, 2001.</ref>
 |-
 ! Parameter
 ! [[Trastuzumab]]
 |-
-! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
+! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
 ! 1.7
 |-
-! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
+! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
 ! 203000
 |-
-! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
+! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
 ! 54
 |-
-! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (days)
+! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (days)
 ! 27
 |-
-! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ug/ml/hr)
+! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ug/ml/hr)
 ! 45036
 |-
-! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
+! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h)
 ! .009
 |-